	US 12,133,880 B2
	Compositions and methods for treatment of GCase related disease states
Ying Sun, Mason, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
Filed on Feb. 25, 2022, as Appl. No. 17/680,375.
Application 16/860,319 is a division of application No. 15/896,423, filed on Feb. 14, 2018, granted, now 10,675,328, issued on Jun. 9, 2020.
Application 17/680,375 is a continuation of application No. 16/860,319, filed on Apr. 28, 2020, granted, now 11,260,106.
Claims priority of provisional application 62/458,628, filed on Feb. 14, 2017.
Prior Publication US 2023/0000948 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 25/28 (2006.01); C12N 7/00 (2006.01)

CPC A61K 38/1777 (2013.01) [A61K 9/0019 (2013.01); A61K 38/47 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); A61P 25/28 (2018.01); C12N 7/00 (2013.01); C12Y 302/01045 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0362 (2013.01); A61K 48/00 (2013.01); C12N 2740/15041 (2013.01); C12N 2740/16043 (2013.01)]

11 Claims

1. A method of treating Gaucher disease in an individual in need thereof, comprising administering to said individual an Integrin α4β1, Very Late Antigen-4 positive neural precursor cell (“VLA4+NPC”), said VLA4+NPC being transfected with a lentivirus comprising wild type glucocerebrosidase (GCase).